Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Table 4

Univariate analysis of the association between expression levels of pentose phosphate pathway-related proteins in metastatic breast cancers and overall survival by the log-rank test.

Parameters	Total, (%)		Metastatic site
			Bone, (%)		Brain, (%)		Liver, (%)		Lung, (%)
	Mean survival	value	Mean survival	value	Mean survival	value	Mean survival	value	Mean survival	value
	(95% CI) months		(95% CI) months		(95% CI) months		(95% CI) months		(95% CI) months
G6PDH
Negative	109 (79–138)	0.732	65 (50–79)	0.390	24 (20–28)	0.534	80 (47–112)	0.761	102 (53–150)	0.064
Positive	116 (99–132)		79 (51–108)		106 (82–129)		60 (28–92)		142 (116–168)
6PGL
Negative	116 (99–133)	0.599	101 (68–133)	0.040	111 (83–139)	0.716	n/a	n/a	n/a	n/a
Positive	94 (62–127)		43 (23–64)		65 (44–87)		n/a		n/a
6PGDH
Negative	114 (98–129)	0.976	n/a	n/a	n/a	n/a	n/a	n/a	136 (111–160)	0.002
Positive	71 (27–115)		n/a		n/a		n/a		17 (17–17)
NRF2 (cytoplasm)
Negative	108 (92–125)	0.079	n/a	n/a	90 (61–119)	0.123	n/a	n/a	n/a	n/a
Positive	108 (91–126)		n/a		105 (82–128)		n/a		n/a
NRF2 (nuclei)
Negative	115 (99–131)	0.964	91 (62–120)	0.340	100 (74–127)	0.573	n/a	n/a	n/a	n/a
Positive	71 (55–86)		62 (36–87)		79 (56–102)		n/a		n/a

CI, confidential interval; G6PDH, glucose-6-phosphate dehydrogenase; 6PGL, 6-phosphogluconolactonase; n/a, not applicable; 6PGDH, 6-phosphogluconate dehydrogenase; NRF2, nuclear factor erythroid 2- (NF-E2-) related factor 2.